{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:49:10Z","timestamp":1792756150045,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006668","name":"Fondo para la Investigaci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.exer.2019.107697","type":"journal-article","created":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T11:08:18Z","timestamp":1560942498000},"page":"107697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["In vivo effect of bevacizumab-loaded albumin nanoparticles in the treatment of corneal neovascularization"],"prefix":"10.1016","volume":"185","author":[{"given":"In\u00e9s","family":"Luis de Red\u00edn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Boiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Recalde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maite","family":"Ag\u00fceros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Allemandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M.","family":"Llabot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Garc\u00eda-Layana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M.","family":"Irache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exer.2019.107697_bib1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.phrs.2015.11.027","article-title":"Targeting VEGF in eye neovascularization: what's new? A comprehensive review on current therapies and oligonucleotide-based interventions under development","volume":"103","author":"Amadio","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.exer.2019.107697_bib2","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nature05249","article-title":"Corneal avascularity is due to soluble VEGF receptor-1","volume":"443","author":"Ambati","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.exer.2019.107697_bib3","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/IAE.0000000000001181","article-title":"Intravitreal bevacizumab for proliferative diabetic retinopathy: results from the pan-American collaborative retina study group (Pacores) at 24 months of follow-up","volume":"37","author":"Arevalo","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.exer.2019.107697_bib4","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2147\/OPTH.S8372","article-title":"Ocular onchocerciasis: current management and future prospects","volume":"5","author":"Babalola","year":"2011","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107697_bib5","first-page":"519","article-title":"Efficacy of topical bevacizumab in high-risk corneal transplant survival","volume":"29","author":"Bhatti","year":"2013","journal-title":"Pakistan J. Med. Sci."},{"key":"10.1016\/j.exer.2019.107697_bib6","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/bjophthalmol-2013-303887","article-title":"Regression of mature lymphatic vessels in the cornea by photodynamic therapy","volume":"98","author":"Bucher","year":"2014","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107697_bib7","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.survophthal.2012.01.007","article-title":"Corneal neovascularization: an anti-VEGF therapy review","volume":"57","author":"Chang","year":"2012","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107697_bib8","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2165\/00003495-200868080-00002","article-title":"Neovascular age-related macular degeneration: potential therapies","volume":"68","author":"Chappelow","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.exer.2019.107697_bib9","first-page":"S70","article-title":"Intravitreal bevacizumab injection in advanced retinopathy of prematurity","volume":"95","author":"Choovuthayakorn","year":"2012","journal-title":"J. Med. Assoc. Thail."},{"key":"10.1016\/j.exer.2019.107697_bib10","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s004170050118","article-title":"Effect of 0.1% dexamethasone on epithelial healing in experimental corneal alkali wounds\u202f: morphological changes during the repair process","volume":"236","author":"Chung","year":"1998","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107697_bib11","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s004170100313","article-title":"Impact of short-term versus long-term topical steroids on corneal neovascularization after non-high-risk keratoplasty","volume":"239","author":"Cursiefen","year":"2001","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107697_bib12","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/archophthalmol.2009.18","article-title":"Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, non-comparative study","volume":"127","author":"Dastjerdi","year":"2009","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107697_bib13","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ejps.2011.12.016","article-title":"Modified Rose Bengal assay for surface hydrophobicity evaluation of cationic solid lipid nanoparticles (cSLN)","volume":"45","author":"Doktorovova","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.exer.2019.107697_bib14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.5505\/tjtes.2014.63993","article-title":"The effects of oral antibiotics on infection prophylaxis in traumatic wounds","volume":"20","author":"Erbil","year":"2014","journal-title":"Turkish J. Trauma Emerg. Surg."},{"key":"10.1016\/j.exer.2019.107697_bib15","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.survophthal.2012.01.005","article-title":"Herpes simplex epithelial and stromal keratitis: an epidemiologic update","volume":"57","author":"Farooq","year":"2012","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107697_bib16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40662-017-0094-6","article-title":"Therapeutic approaches for corneal neovascularization","volume":"4","author":"Feizi","year":"2017","journal-title":"Eye Vis."},{"key":"10.1016\/j.exer.2019.107697_bib17","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","article-title":"Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy","volume":"333","author":"Ferrara","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.exer.2019.107697_bib18","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1097\/ICO.0000000000000849","article-title":"Efficacy of subconjunctival aflibercept versus bevacizumab for prevention of corneal neovascularization in a rat model","volume":"35","author":"Gal-Or","year":"2016","journal-title":"Cornea"},{"key":"10.1016\/j.exer.2019.107697_bib19","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ejpb.2015.01.010","article-title":"Mimicking microbial strategies for the design of mucus-permeating nanoparticles for oral immunization","volume":"96","author":"Gamazo","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.exer.2019.107697_bib20","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1200\/JCO.2008.21.6630","article-title":"Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer","volume":"27","author":"Gray","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.exer.2019.107697_bib21","first-page":"48","article-title":"New controlled release technologies broaden opportunities for ophthalmic therapies","volume":"8","author":"Haders","year":"2008","journal-title":"Drug Deliv. Technol."},{"key":"10.1016\/j.exer.2019.107697_bib22","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ejpb.2014.12.021","article-title":"In vivo study of the mucus-permeating properties of PEG-coated nanoparticles following oral administration","volume":"97","author":"Inchaurraga","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.exer.2019.107697_bib23","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/ICO.0000000000000403","article-title":"Prevention and treatment of corneal graft rejection: current practice patterns of the Cornea Society (2011)","volume":"34","author":"Kharod-Dholakia","year":"2015","journal-title":"Cornea"},{"key":"10.1016\/j.exer.2019.107697_bib24","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/178132","article-title":"Treatment of corneal neovascularization using anti-VEGF bevacizumab","volume":"2014","author":"Krizova","year":"2014","journal-title":"J. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107697_bib25","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3390\/polym3010193","article-title":"Recent advances in ocular drug delivery systems","volume":"3","author":"Kuno","year":"2011","journal-title":"Polymers"},{"key":"10.1016\/j.exer.2019.107697_bib26","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.addr.2008.11.002","article-title":"Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues","volume":"61","author":"Lai","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.exer.2019.107697_bib27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3341\/kjo.1993.7.1.25","article-title":"Treatment of corneal neovascularization with argon laser","volume":"7","author":"Lim","year":"2013","journal-title":"Korean J. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107697_bib28","doi-asserted-by":"crossref","first-page":"252","DOI":"10.5935\/0004-2749.20170061","article-title":"Effects of topical and subconjunctival use of bevacizumab on corneal neovascularization in rabbits' eyes","volume":"80","author":"Lopes","year":"2017","journal-title":"Arq. Bras. Oftalmol."},{"key":"10.1016\/j.exer.2019.107697_bib29","first-page":"1","article-title":"Corneal neovascularization: a combined approach of bevacizumab and suramin showed increased antiangiogenic effect through downregulation of BFGF and P2X2","volume":"21","author":"Lopez","year":"2017","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.exer.2019.107697_bib30","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ijpharm.2018.02.003","article-title":"Human serum albumin nanoparticles for ocular delivery of bevacizumab","volume":"541","author":"Luis de Red\u00edn","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"2008","key":"10.1016\/j.exer.2019.107697_bib31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ijpharm.2008.02.009","article-title":"New environmental sensitive system for colon-specific delivery of peptidic drugs","volume":"358","author":"Luppi","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.exer.2019.107697_bib32","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3109\/02713688508999984","article-title":"Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea","volume":"4","author":"Mahoney","year":"1985","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.exer.2019.107697_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rinphs.2015.06.001","article-title":"Development and characterization of in-situ gel for ophthalmic formulation containing ciprofloxacin hydrochloride","volume":"6","author":"Makwana","year":"2016","journal-title":"Results Pharma Sci."},{"key":"10.1016\/j.exer.2019.107697_bib34","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40005-017-0324-x","article-title":"Fabrication and characterization of mucoadhesive topical nanoformulations of dorzolamide HCl for ocular hypertension","volume":"48","author":"Manchanda","year":"2017","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.exer.2019.107697_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2015.07.001","article-title":"Corneal structure and transparency","volume":"49","author":"Meek","year":"2015","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.exer.2019.107697_bib36","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.2353\/ajpath.2007.070172","article-title":"Dexamethasone inhibits interleukin-1\u03b2-induced corneal neovascularization\u202f: role of nuclear factor-\u03baB-activated stromal cells in inflammatory angiogenesis","volume":"171","author":"Nakao","year":"2007","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.exer.2019.107697_bib37","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5935\/0004-2749.20140054","article-title":"Comparison of the effects of subconjunctival and topical anti-VEGF therapy (bevacizumab) on experimental corneal neovascularization","volume":"77","author":"Ozdemir","year":"2014","journal-title":"Arq. Bras. Oftalmol."},{"key":"10.1016\/j.exer.2019.107697_bib38","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.exer.2019.107697_bib39","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000329603","article-title":"Epidemiology of major eye diseases leading to blindness in Europe: a literature review","volume":"47","author":"Prokofyeva","year":"2012","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.exer.2019.107697_bib40","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1097\/ICO.0b013e31817c41e3","article-title":"Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization","volume":"27","author":"Qian","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.exer.2019.107697_bib41","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1586\/eop.13.8","article-title":"Corneal neovascularization: a review of the molecular biology and current therapies","volume":"8","author":"Rolfsen","year":"2013","journal-title":"Expert Rev. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107697_bib50","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0378-5173(96)04663-7","article-title":"Evaluation of ocular permeation enhancers: In vitro effects on corneal transport of four \u03b2-blockers, and in vitro\/in vivo toxic activity","volume":"142","author":"Saettone","year":"1996","journal-title":"Int. J. Pharm"},{"key":"10.1016\/j.exer.2019.107697_bib42","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4103\/ijo.IJO_870_16","article-title":"Chlamydial eye infections: current perspectives","volume":"65","author":"Satpathy","year":"2017","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107697_bib43","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.exer.2016.03.021","article-title":"Efficacy of topical aflibercept versus topical bevacizumab for the prevention of corneal neovascularization in a rat model","volume":"146","author":"Sella","year":"2016","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.exer.2019.107697_bib44","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000320006","article-title":"Mechanisms of ocular angiogenesis and its molecular mediators","volume":"46","author":"Siemerink","year":"2010","journal-title":"Dev. Ophthalmol."},{"issue":"66","key":"10.1016\/j.exer.2019.107697_bib45","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4103\/ijo.IJO_646_17","article-title":"Anatomy of cornea and ocular surface","volume":"2018","author":"Sridhar","year":"2018","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107697_bib47","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1167\/iovs.02-0346","article-title":"Topical nepafenac inhibits ocular neovascularization","volume":"2003","author":"Takahashi","year":"2003","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2019.107697_bib48","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.addr.2006.07.027","article-title":"Challenges and obstacles of ocular pharmacokinetics and drug delivery","volume":"58","author":"Urtti","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.exer.2019.107697_bib49","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/jps.20685","article-title":"Flurbiprofen loaded biodegradable nanoparticles for ophtalmic administration","volume":"95","author":"Vega","year":"2006","journal-title":"J. Pharm. Sci."}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483519300776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483519300776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T05:03:33Z","timestamp":1757999013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014483519300776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":49,"alternative-id":["S0014483519300776"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2019.107697","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vivo effect of bevacizumab-loaded albumin nanoparticles in the treatment of corneal neovascularization","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2019.107697","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107697"}}